Any offers? Or rejections?

Quote
Anonymous said:
Trollsuka-please stay put. Such a fabricated story. Pricing hasn't and won't be discussed at this point. Lots of reasons across the board but you'll never know now will you?
Click to expand...

Your CEO has discussed price in press releases. He's mentioned it would be priced comparable to the other LAIs in the market but "creative pricing" would be considered where appropriate. It was in an analysts' day conference. His words. So, yes, you have discussed pricing.
 






Anonymous said:
Your CEO has discussed price in press releases. He's mentioned it would be priced comparable to the other LAIs in the market but "creative pricing" would be considered where appropriate. It was in an analysts' day conference. His words. So, yes, you have discussed pricing.
Click to expand...

Nice argument. So if I say the word price, creative pricing, or comparable pricing then I've discussed pricing. So you can conclude what from my "discussion"? Zactly.
 






From the CEO's comments you would guess that it would be dosed somewhere around the equivalent of the Sustenna and Maintena doses. As for creative pricing that means aggressive contracting where it makes sense in key markets with key customers. Did you just fall off a potato truck?
 












Revenues

Manufacturing and royalty revenues from the company’s long-acting atypical antipsychotic franchise, RISPERDAL® CONSTA® and INVEGA® SUSTENNA®/XEPLION®, were $46.9 million, compared to $49.6 million for the same period in the prior year.
 












Anonymous said:
From the CEO's comments you would guess that it would be dosed somewhere around the equivalent of the Sustenna and Maintena doses. As for creative pricing that means aggressive contracting where it makes sense in key markets with key customers. Did you just fall off a potato truck?
Click to expand...

Nice assumption riddled conclusions. Glad you know the price now.
 






so please demonstrate why this over maintanna. minus a price difference why would it be used. please hint at a reason if you dont want to be specific. anything? not trying to be sarcastic but there is nothing there that i see.. i feel like everyone is pretending this drug will sell in hopes that somehow the doctors will see some pretend benefit over for example maintanna (what a stupid name that is. Every time someone says it i begin to laugh.) Is this new drug going to be called continua or stayona or once a montha tooa
 












Anonymous said:
so please demonstrate why this over maintanna. minus a price difference why would it be used. please hint at a reason if you dont want to be specific. anything? not trying to be sarcastic but there is nothing there that i see.. i feel like everyone is pretending this drug will sell in hopes that somehow the doctors will see some pretend benefit over for example maintanna (what a stupid name that is. Every time someone says it i begin to laugh.) Is this new drug going to be called continua or stayona or once a montha tooa
Click to expand...

Abilify is not first line option for schizophrenia. In any form. People are interested in this company for their pipeline. It's pretty good.
 






do you know how many times over the years i 've heard come to our company but not for this new drug but the pipeline. think of the pain for the next year selling an absolute dog just to find the next drug is delayed another year or longer. if you have less then 10 years of sales,dont have or will be losing a job i get it but leaving a place for this is a bigger mistake.

making an extra 10 k salary might not be worth the endless micromanging of what will be a slow launch unless there are very reasonable sales goals.

good luck but you have to decide soon. This place is a single at best. Dont you deserve a triple or home run at this point in your career.
 






Anonymous said:
so please demonstrate why this over maintanna. minus a price difference why would it be used. please hint at a reason if you dont want to be specific. anything? not trying to be sarcastic but there is nothing there that i see.. i feel like everyone is pretending this drug will sell in hopes that somehow the doctors will see some pretend benefit over for example maintanna (what a stupid name that is. Every time someone says it i begin to laugh.) Is this new drug going to be called continua or stayona or once a montha tooa
Click to expand...

First, very funny on the drug name ideas, lol. This is sales of a completely equivalent molecule, it will come down to who sells better, which in this market means, RAPPORT AND RELATIONSHIPS! Price will matter for this reason: 90+% of patients with SZ are either on your state medicaid or medicare (disabled), which means taxpayers are springing for their care entirely. Docs, NP's, etc. all care about this as it comes out of their pockets, therefore, the slightest reduction in price that can be marketed will matter. this is why everyone loves Haldol. I'll add that there may be a benefit to 3 doses vs. 2. It gives providers more flexibility and a higher dose not offered with Maintena. Delivery is said to be better as well. "stayona".....hilarious! Thanks for the laugh!
 






Anonymous said:
First, very funny on the drug name ideas, lol. This is sales of a completely equivalent molecule, it will come down to who sells better, which in this market means, RAPPORT AND RELATIONSHIPS! Price will matter for this reason: 90+% of patients with SZ are either on your state medicaid or medicare (disabled), which means taxpayers are springing for their care entirely. Docs, NP's, etc. all care about this as it comes out of their pockets, therefore, the slightest reduction in price that can be marketed will matter. this is why everyone loves Haldol. I'll add that there may be a benefit to 3 doses vs. 2. It gives providers more flexibility and a higher dose not offered with Maintena. Delivery is said to be better as well. "stayona".....hilarious! Thanks for the laugh!
Click to expand...
All the names are around expanded length of deliver- 2 weeks to a month, to soon to be three months and on and on....all the names sound like the syntax of a Baptist minister in a country church many years ago. I'm a Maintena Account Manager that did not go to Alkermes. I think it will be a good move for many of my friends who went there but the truth is we have sold the molecule and the need to use an LAI to prevent relapse. The only advantages that will matter are contracts on Medicaid. Availability on Part D plans and a gluteal and deltoid injection site. We have sold the product, helped sell the use of an LAI along with Janssen and we are growing this business.I hope Otsuka/Lundbeck gets the contracts right or the business will be yours as a gift from us to you. Good Luck to my friends who have left, in the end it's about helping the mentally ill and paying our bills with gainful employment.
 












Anonymous said:
All the names are around expanded length of deliver- 2 weeks to a month, to soon to be three months and on and on....all the names sound like the syntax of a Baptist minister in a country church many years ago. I'm a Maintena Account Manager that did not go to Alkermes. I think it will be a good move for many of my friends who went there but the truth is we have sold the molecule and the need to use an LAI to prevent relapse. The only advantages that will matter are contracts on Medicaid. Availability on Part D plans and a gluteal and deltoid injection site. We have sold the product, helped sell the use of an LAI along with Janssen and we are growing this business.I hope Otsuka/Lundbeck gets the contracts right or the business will be yours as a gift from us to you. Good Luck to my friends who have left, in the end it's about helping the mentally ill and paying our bills with gainful employment.
Click to expand...

To the above poster and fellow Otsuka colleague I will say you should have done your homework and interviewed. This company has tremendous potential and not just with this product. I accepted my offer with Alkermes on Friday and it was very strong both base and bonus. Otsuka's pipeline is very shakey at best over the next 3-5 years. Good luck to you but bad move
 






There are far too many idiots on here.
how someone discusses price that is dictated by internal organizations trade group is odd. So pops said it would be price comparable to competitors- of course it will dumb ass! Will there be differences because of other options related to the product, of course. Contracts with Medicaid/ Medicare among others will obviously play a role in success but if you have spent any time in LAI world you know that NO company negotiates for exclusive contracts- it's about parity access so physicans have options in an area of healthcare that demands multiple options- this is not selling nexium over Prilosec or Prevacid- this is serious shit- shit that matters not heartburn.
Get it right people- you clearly have no idea what's involved in this and what factors should be considered. I'll also add to the naysayers that Alkermes has a lot of good things happening- this product is a good step for them but other significant products are in development.
It's a better company then the competitors and there is significantly more money to be made.
If you differ then go back to dropping samples sunovian folks and sharing territory at Otsuka with 3-4 partners! Soon you ll be selling laughing product and yet another branded tab in psych! Get out folks
 






Aripiprazole lauroxil is an injectable atypical antipsychotic with one-month and two-month formulations in development for the treatment of schizophrenia.

That's the big deal. A 2 month injectable would be unique.
 






Top Bottom
Back
Quote